Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002;2002(1):CD002170.
doi: 10.1002/14651858.CD002170.

Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease

F S Ram  1 , D M Brocklebank, M Muers, J Wright, P W Jones
Affiliations

Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease

F S Ram et al. Cochrane Database Syst Rev. 2002.

Abstract

Background: Bronchodilator therapy for COPD may be delivered by a number of different inhaler devices.

Objectives: To determine the efficacy of pressurised metered dose inhalers (pMDI) compared to any other handheld inhaler device for the delivery of bronchodilators in non-acute COPD.

Search strategy: The Cochrane Collaboration, Asthma and Wheeze Randomised Controlled Clinical Trials register was searched for studies. The UK pharmaceutical companies who manufacture inhaled COPD medication were also contacted.

Selection criteria: Two reviewers independently reviewed the results of computerised search and any potentially relevant articles were obtained in full.

Data collection and analysis: One reviewer extracted details of each trial and a second reviewer checked all extracted data. Dichotomous outcomes such as exacerbation rate were assessed using relative risk, with 95% confidence interval (CI).

Main results: Fourteen studies appeared potentially relevant but only three studies (61 patients) met the entry criteria. Two studies compared a dry powder device (Turbuhaler or Rotahaler) with a pMDI for beta2-agonist delivery, and one (36 patients cross-over design) the Respimat (soft mist device for ipratropium) vs a pMDI. For the Turbuhaler and Rotahaler, none of the reported outcome measures were significantly different. The Rotahaler study used a high and low dose of medication with or without large volume spacer. The study using the Respimat showed significant increases in FEV1 when compared to a pMDI (difference in change from base line 70 ml, 95% CI 10, 130 ml). The effect on change in FVC was of similar size. There were no differences between these two devices for any other reported outcomes. Although none of the included studies required prior patient ability to use any of the inhalers (and no study mentioned device training), it was assumed that all patients randomised into the study would have undergone training in use of the study inhalers and were capable of using those devices.

Reviewer's conclusions: In patients with stable COPD, pMDI produced similar outcomes to a dry powder device for delivering beta2-agonists, but the very small number of studies and included patients does not permit firm conclusions to be drawn. The soft mist device for ipratropium was more effective than a pMDI, but the data come from one small study. There need to be further well designed randomised controlled trials to define the role of inhaler devices using bronchodilators in stable COPD.

PubMed Disclaimer

Conflict of interest statement

There are no known conflicts of interest.

References

References to studies included in this review

Formgren 1994a {published data only}
    1. Formgren H, Sjokvist A, Stahl E, Wiren JE. Terbutaline in COPD comparison between turbuhaler and chloroflurocarbon (CFC) inhaler. Lung 1994;172:271‐80. - PubMed
Formgren 1994b {published data only}
    1. Formgren H, Sjokvist A, Stahl E, Wiren JE. Terbutaline in COPD comparison between turbuhaler and chloroflurocarbon (CFC) inhaler. Lung 1994;172:271‐80. - PubMed
Iacono 2000 {published data only}
    1. Iacono P, Velicitat P, Guemas E, Leclerc V, Thebault JJ. Improved delivery of ipratropium bromide using Respimat (a new soft mist inhaler) compared with a conventional metered dose inhaler: cumulative dose response study in patients with COPD. Respiratory Medicine 2000;94(5):490‐5. [MEDLINE: ; UI: 20324565] - PubMed
Ikeda 1999a {published and unpublished data}
    1. Ikeda A, Nishimura K, Koyama H, Tsukino M, Hajiro T, Mishima M, et al. Comparison of the bronchodilator effects of salbutamol delivered via a metered‐dose inhaler with spacer, a dry‐powder inhaler, and a jet nebulizer in patients with chronic obstructive pulmonary disease. Respiration 1999;66:119‐23. - PubMed
Ikeda 1999b {published and unpublished data}
    1. Ikeda A, Nishimura K, Koyama H, Tsukino M, Hajiro T, Mishima M, et al. Comparison of the bronchodilator effects of salbutamol delivered via a metered‐dose inhaler with spacer, a dry‐powder inhaler, and a jet nebulizer in patients with chronic obstructive pulmonary disease. Respiration 1999;66:119‐23. - PubMed

References to studies excluded from this review

Bellamy 1981 {published data only}
    1. Bellamy D, Hutchison DC. The effects of salbutamol aerosol on lung function in patients with pulmonary emphysema. British Journal of Diseases of the Chest 1981;75(2):190‐6. [UID: 82000341] - PubMed
Cushley 1983 {published data only}
    1. Cushley MJ, Lewis RA, Tattersfield AE. Comparison of three techniques of inhalation on the airway response to terbutaline. Thorax 1983;38:908‐13. - PMC - PubMed
Gimeno 1988 {published data only}
    1. Gimeno F, Veenen R, Berg W, Steenhuis E. A placebo‐controlled comparison between the bronchodilatory effects of ipratropium bromide inhaled as a dry powder and by metered dose inhaler in chronic obstructive pulmonary disease. Annals of Allergy 1988;61:341‐3. - PubMed
Harvey 1992 {published data only}
    1. Harvey J, Williams JG. Randomised cross‐over comparison of five inhaler systems for bronchodilator therapy. British Journal of Clinical Practice 1992;46(4):249‐51. [UID: 93176620] - PubMed
Iversen 1999 {published data only}
    1. Iversen ET, Sorensen T, Heckscher T, Jensen JI. Effect of terbutaline on exercise capacity and pulmonary function in patients with chronic obstructive pulmonary disease. Lung 1999;177:263‐71. - PubMed
Larsen 1998 {published data only}
    1. Larsen KR, Svendsen UG, Molgaard F, Petersen BN. Comparability of albuterol delivered by a piezoelectric device versus metered dose inhaler in patients with chronic obstructive airways disease. Journal of Aerosol Medicine 1998;11(2):81‐8. - PubMed
Mutterlein 1990 {published data only}
    1. Mutterlein VR, Schmidt G, Fleischer W, Freund E. A new inhalation system for bronchodilation. A study of the acceptance of the Ingelheim M inhalator by chronic obstructive pulmonary disease patients [Ein neues Inhalationssystem zur Bronchodilation]. Fortscritte der Therapie (Pneumologie) 1990;108(11):225‐8/61‐6. - PubMed
Petersen 1983 {published data only}
    1. Petersen LN, Petersen BN. Fenoterol inhalation powder and aerosol. European Journal of Respiratory Disease 1983;64(Suppl 130):1‐5. [UID: 84084909] - PubMed
van der Palen 1995 {published data only}
    1. Palen J, Klein JJ, Kerkhoff AH, Herwaarden CL. Evaluation of the effectiveness of four different inhalers in patients with chronic obstructive pulmonary disease. Thorax 1995;50(11):1183‐7. - PMC - PubMed
van der Palen 1998 {published data only}
    1. Palen J, Klein JJ, Schildkamp AM. Comparison of a new multidose powder inhaler (diskus/accuhaler) and turbuhaler regarding preference and ease of use. Journal of Asthma 1998;35(2):147‐52. - PubMed
Wetterlin 1988 {published data only}
    1. Wetterlin K. Turbuhaler: a new powder inhaler for administration of drugs to the airways. Pharmacological Research 1988;5(8):506‐8. [UID: 89220804] - PubMed

Additional references

Anthonisen 1994
    1. Anthonisen NR, Commett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. Journal of the American Medical Association 1994;272(19):1497‐505. [UID: 95056307] - PubMed
ATS 1995
    1. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Journal of Respiratory & Critical Care Medicine 1995;152(5 Pt 2):S77‐121. [UID: 96048961] - PubMed
BTS 1997
    1. British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD Guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997;52(Suppl 5):S1‐S28. [UID: 98134513] - PMC - PubMed
ERS 1995
    1. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. European Respiratory Journal 1995;8(8):1398‐420. [UID: 96087552] - PubMed
Jadad 1996
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary ?. Control Clinical Trials 1996;17(1):1‐12. [UID: 96308458] - PubMed
Newman 1998
    1. Newman SP, Brown J, Steed KP, Reader SJ, Kladders H. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparisons of RMT with conventional metered‐dose inhalers with and without spacer devices. Chest 1998;113:957‐63. - PubMed
Nisar 1990
    1. Nisar M, Walshaw M, Earis JE, Pearson MG, Calverley PM. Assessment of reversibility of airways obstruction in patients with chronic obstructive pulmonary disease. Thorax 1990;45(3):190‐4. [UID: 90232464] - PMC - PubMed
O'Driscoll 1997
    1. O'Driscoll BR. Nebulisers for chronic obstructive pulmonary disease. Thorax 1997;52(Suppl 2):S49‐S52. [UID: 97300831] - PMC - PubMed

Publication types

MeSH terms